Middle East Pharmaceutical Industries Company SJSC TADAWUL:4016:
AVALON PHARMA Q1 SALES SAR 130.13 MILLION
AVALON PHARMA Q1 NET PROFIT SAR 26.9 MILLION
AVALON PHARMA- QUARTER SAW OVERALL GROWTH REMAINED RESILIENT DESPITE GEOPOLITICAL DISRUPTIONS
AVALON PHARMA- QUARTER SAW EXPORT SALES REFLECTED A TEMPORARY REPHASING IMPACT
AVALON PHARMA- QUARTER SAW NEW CUSTOMER ONBOARDING, STRONGER SELL-OUT RATES, TARGETED TRADE ACTIVATION INITIATIVES